A detailed history of Black Rock Inc. transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 320,247 shares of AADI stock, worth $915,906. This represents 0.0% of its overall portfolio holdings.

Number of Shares
320,247
Previous 1,041,006 69.24%
Holding current value
$915,906
Previous $2.44 Million 80.82%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.46 - $2.31 $1.05 Million - $1.66 Million
-720,759 Reduced 69.24%
320,247 $467,000
Q1 2024

May 10, 2024

SELL
$1.59 - $2.44 $64,593 - $99,125
-40,625 Reduced 3.76%
1,041,006 $2.44 Million
Q4 2023

Feb 13, 2024

BUY
$1.97 - $5.41 $149,375 - $410,213
75,825 Added 7.54%
1,081,631 $2.18 Million
Q3 2023

Nov 13, 2023

SELL
$4.84 - $7.13 $54,779 - $80,697
-11,318 Reduced 1.11%
1,005,806 $4.87 Million
Q2 2023

Aug 11, 2023

BUY
$6.84 - $8.56 $964,159 - $1.21 Million
140,959 Added 16.09%
1,017,124 $6.96 Million
Q1 2023

May 12, 2023

SELL
$6.85 - $13.0 $107,531 - $204,074
-15,698 Reduced 1.76%
876,165 $6.34 Million
Q4 2022

Feb 13, 2023

BUY
$11.99 - $14.5 $399,998 - $483,734
33,361 Added 3.89%
891,863 $11.4 Million
Q3 2022

Nov 14, 2022

SELL
$12.03 - $14.22 $531,425 - $628,168
-44,175 Reduced 4.89%
858,502 $12.1 Million
Q2 2022

Aug 12, 2022

BUY
$11.57 - $17.92 $6.86 Million - $10.6 Million
592,550 Added 191.07%
902,677 $11.1 Million
Q1 2022

May 12, 2022

BUY
$16.65 - $24.97 $9,540 - $14,307
573 Added 0.19%
310,127 $5.26 Million
Q4 2021

Feb 10, 2022

BUY
$19.32 - $29.02 $5.67 Million - $8.51 Million
293,304 Added 1804.95%
309,554 $7.48 Million
Q3 2021

Nov 09, 2021

BUY
$25.52 - $41.85 $414,700 - $680,062
16,250 New
16,250 $478,000

Others Institutions Holding AADI

About Aadi Bioscience, Inc.


  • Ticker AADI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,016,800
  • Market Cap $60.1M
  • Description
  • Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...
More about AADI
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.